SCHEMBL6936582

SCHEMBL6936582

Cc1ccc2oc(CN(Cc3ccccc3)C(=O)Nc3c(F)cc(F)cc3F)c(-c3ccccc3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
PTPN1 P18031 2/20 0.43
ALDH1A1 P00352 4/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
TACR1 P25103 1/20 0.39
EGFR P00533 1/20 0.38
MAPT P10636 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
POLB P06746 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PTGES O14684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9211389 0.97 MEN1 (0.46) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9209170 0.96 MEN1 (0.46) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL5500482 0.94 MEN1 (0.44) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9212111 0.94 MEN1 (0.44) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9213248 0.91 KMT2A (0.40) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9213879 0.89 L3MBTL1 (0.39) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9213319 0.89 EGFR (0.40) L3MBTL1PTPN1ALDH1A1NPSR1TACR1
SCHEMBL9218677 0.89 L3MBTL1 (0.39) L3MBTL1MEN1KMT2APTPN1ALDH1A1
SCHEMBL9215732 0.88 EGFR (0.38) L3MBTL1MEN1KMT2APTPN1NPSR1
SCHEMBL9221161 0.87 L3MBTL1 (0.38) L3MBTL1MEN1KMT2APTPN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2003513909-A 2003-04-15 JP claimed
EP-1229907-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-08-14 EP claimed
WO-2001034127-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-05-17 WO claimed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP claimed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO claimed
EP-1229907-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-08-14 EP disclosed
WO-2001034127-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-05-17 WO disclosed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed